Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease.

[1]  M. Wolf,et al.  Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. , 2022, Journal of hepatology.

[2]  A. Sanyal,et al.  Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. , 2022, Journal of hepatology.

[3]  A. Sanyal,et al.  Breakthroughs in therapies for NASH and remaining challenges. , 2022, Journal of hepatology.

[4]  Shimona Starling.  A new GLP1, GIP and glucagon receptor triagonist , 2022, Nature Reviews Endocrinology.

[5]  B. Neuschwander‐Tetri,et al.  Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. , 2022, Journal of hepatology.

[6]  R. Loomba,et al.  Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  M. Ziol,et al.  Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. , 2021, The Lancet. Oncology.

[8]  Hongliang Li,et al.  Targeting ACC for NASH resolution. , 2021, Trends in molecular medicine.

[9]  A. Sanyal,et al.  Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. , 2021, Gastroenterology.

[10]  B. Neuschwander‐Tetri,et al.  EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. , 2021, Journal of hepatology.

[11]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[12]  B. Neuschwander‐Tetri,et al.  Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. , 2021, The New England journal of medicine.

[13]  V. Wong,et al.  Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis , 2021, Hepatology.

[14]  M. Karsdal,et al.  BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial , 2021, Hepatology.

[15]  L. Kupčinskas,et al.  Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial , 2021, Nature Medicine.

[16]  G. Marchesini,et al.  Non-alcoholic fatty liver disease: A patient guideline , 2021, JHEP reports : innovation in hepatology.

[17]  Y. Eguchi,et al.  Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease , 2021, Alimentary pharmacology & therapeutics.

[18]  B. Neuschwander‐Tetri,et al.  TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. , 2021, Gastroenterology.

[19]  P. Galle,et al.  Impact of thyroid disorders on the incidence of non‐alcoholic fatty liver disease in Germany , 2021, United European gastroenterology journal.

[20]  Ben L. Da,et al.  Semaglutide or Placebo for Nonalcoholic Steatohepatitis. , 2021, The New England journal of medicine.

[21]  T. Rolph,et al.  Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial , 2021, Nature Medicine.

[22]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[23]  E. Schiff,et al.  Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial , 2021, Hepatology.

[24]  D. Drucker,et al.  GIPR Signaling in Immune Cells Maintains Metabolically Beneficial Type 2 Immune Responses in the White Fat From Obese Mice , 2021, Frontiers in Immunology.

[25]  A. Sanyal,et al.  Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases , 2021, JHEP reports : innovation in hepatology.

[26]  M. Bashir,et al.  A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. , 2021, Journal of hepatology.

[27]  Christopher D. Brown,et al.  A genome-wide association study for nonalcoholic fatty liver disease identifies novel genetic loci and trait-relevant candidate genes in the Million Veteran Program. , 2021, medRxiv.

[28]  B. Andersen,et al.  FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human , 2020, Frontiers in Endocrinology.

[29]  F. Anania,et al.  Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration , 2020, Hepatology.

[30]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[31]  V. Wong,et al.  Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH , 2020, Hepatology.

[32]  J. Ludvigsson,et al.  Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease , 2020, Gut.

[33]  J. Trotter,et al.  Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. , 2020, Gastroenterology.

[34]  G. Koch,et al.  Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. , 2020, Journal of hepatology.

[35]  V. Ratziu,et al.  Why do so many NASH trials fail? , 2020, Gastroenterology.

[36]  F. Tacke,et al.  Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. , 2020, Journal of hepatology.

[37]  A. Hollenberg,et al.  Thyroid Hormone Signaling and the Liver , 2020, Hepatology.

[38]  K. Duffin,et al.  Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[39]  K. Clément,et al.  Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. , 2020, Journal of hepatology.

[40]  L. Groop,et al.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. , 2020, JCI insight.

[41]  V. Wong,et al.  Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. , 2020, Journal of hepatology.

[42]  V. Wong,et al.  Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial , 2020, Hepatology.

[43]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[44]  D. Erion,et al.  Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis , 2020, PloS one.

[45]  V. Wong,et al.  Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study , 2020, Hepatology.

[46]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[47]  Marcos C. Pedrosa,et al.  A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. , 2019, Contemporary clinical trials.

[48]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[49]  O. Cummings,et al.  Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease , 2019, JAMA network open.

[50]  B. Singh,et al.  Non-alcoholic fatty liver disease and hypercholesterolemia: Roles of thyroid hormones, metabolites, and agonists. , 2019, Thyroid : official journal of the American Thyroid Association.

[51]  D. Koeberl,et al.  A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia (GSD Ia). , 2019, Thyroid : official journal of the American Thyroid Association.

[52]  P. Bedossa,et al.  Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. , 2019, Contemporary clinical trials.

[53]  U. Kaul,et al.  New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence , 2019, Cardiovascular Diabetology.

[54]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[55]  E. Speliotes,et al.  17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[56]  L. Vonghia,et al.  Pharmacological Treatment for Non-alcoholic Fatty Liver Disease , 2019, Advances in Therapy.

[57]  Richard G. Lee,et al.  Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice , 2019, Molecular metabolism.

[58]  D. Drucker,et al.  GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9 , 2018, Nature Metabolism.

[59]  V. Wong,et al.  Repeating measurements by transient elastography in non‐alcoholic fatty liver disease patients with high liver stiffness , 2018, Journal of gastroenterology and hepatology.

[60]  B. Neuschwander‐Tetri,et al.  Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials , 2018, Hepatology.

[61]  D. Rockey,et al.  Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.

[62]  Dongmei Wang,et al.  Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex , 2018, Front. Endocrinol..

[63]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[64]  J. Trotter,et al.  NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.

[65]  J. Binet,et al.  Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. , 2018, Journal of medicinal chemistry.

[66]  V. Ratziu.  A critical review of endpoints for non-cirrhotic NASH therapeutic trials. , 2018, Journal of hepatology.

[67]  V. Wong,et al.  A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis , 2018, Hepatology.

[68]  G. Shulman,et al.  Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.

[69]  W. Wahli,et al.  Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[70]  Z. Goodman,et al.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial , 2017, Hepatology.

[71]  Shelly C. Lu,et al.  Role of aramchol in steatohepatitis and fibrosis in mice , 2017, Hepatology communications.

[72]  Jonathan C. Cohen,et al.  The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation , 2017, Hepatology.

[73]  C. Mcwherter,et al.  The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice , 2017, Hepatology communications.

[74]  I. Leclercq,et al.  The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis , 2017, Hepatology communications.

[75]  B. Staels,et al.  Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .

[76]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[77]  M. Beekman,et al.  Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice , 2016, Scientific Reports.

[78]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[79]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[80]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[81]  B. Staels,et al.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. , 2016, Annual review of physiology.

[82]  Mary Brophy,et al.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.

[83]  F. Lv,et al.  FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation , 2015, Oncotarget.

[84]  P. Bedossa,et al.  A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy , 2016 .

[85]  P. Bedossa,et al.  Improvement in NASH histological activity highly correlates with fibrosis regression , 2016 .

[86]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[87]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[88]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[89]  A. Suzuki,et al.  Repair-Related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism , 2014, Endocrinology.

[90]  J. Dufour,et al.  Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. , 2014, Journal of hepatology.

[91]  S. So,et al.  Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. , 2014, Journal of medicinal chemistry.

[92]  B. Motta,et al.  Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. , 2014, Biochimica et biophysica acta.

[93]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[94]  L. N. Valenti,et al.  PNPLA3 I148M polymorphism and progressive liver disease. , 2013, World journal of gastroenterology.

[95]  J. Everhart,et al.  Diurnal Variation in Serum Alanine Aminotransferase Activity in the US Population , 2013, Journal of clinical gastroenterology.

[96]  B. Staels,et al.  Roles of PPARs in NAFLD: potential therapeutic targets. , 2012, Biochimica et biophysica acta.

[97]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[98]  M. Yeh,et al.  Peroxisome proliferator‐activated receptor‐α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non‐alcoholic steatohepatitis , 2012, Journal of gastroenterology and hepatology.

[99]  M. Negri,et al.  17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[100]  M. Tschöp,et al.  The metabolic actions of glucagon revisited , 2010, Nature Reviews Endocrinology.

[101]  J. Hardies,et al.  Pioglitazone in the treatment of NASH: the role of adiponectin , 2010, Alimentary pharmacology & therapeutics.

[102]  M. Martínez-Chantar,et al.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[103]  B. S. Mohammed,et al.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. , 2010, The Journal of clinical endocrinology and metabolism.

[104]  K. Cusi,et al.  Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[105]  L. J. Hardies,et al.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis , 2009, Hepatology.

[106]  K. Laugero,et al.  Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[107]  H. Iwasaka,et al.  An antisense oligonucleotide to HSP47 inhibits paraquat-induced pulmonary fibrosis in rats. , 2007, Toxicology.

[108]  B. Spiegelman,et al.  International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors , 2006, Pharmacological Reviews.

[109]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[110]  Ronald J A Wanders,et al.  Biochemistry of mammalian peroxisomes revisited. , 2006, Annual review of biochemistry.

[111]  T. Tuschl,et al.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate , 2001, The EMBO journal.

[112]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[113]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[114]  J. Sauk,et al.  Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. , 1994, The Journal of biological chemistry.

[115]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[116]  S. J. Hampson.  Nursing interventions for the first three postpartum months. , 1989, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.